drugset / Trial / NCT02233712
Open-label, Dose-finding Study to Determine Antibody Response to G17DT Treatment in Patients With Gastric Cancer.
Non-randomizedSingle-groupOpen-labelTreatment
Summary
An open label, dose-finding, schedule-changing, sequential, multiple dose, multi-center study in patients with Stage I-III gastric cancer. The first group of patients received a starting dose of 250 µg at weeks 0, 1, and 3. Thereafter, allocation to treatment with 100 µg or 500 µg was based on antibody response and dose tolerability.
Timeline
- Start
- 1999-08
- Primary completion
- 2000-03
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | G17DT Immunogen | Vaccine | 100 ug | — |
| Subject | G17DT Immunogen | Vaccine | 250 ug | — |
| Subject | G17DT Immunogen | Vaccine | 500 ug | — |